Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Pharmacogenomics is Scopus-indexed (Q3, CiteScore 3), WoS SCIE. Published by Taylor and Francis Ltd..
Checked against the index lists dated .
ISSN 1462-2416Verify ISSN ↗1744-8042Verify ISSN ↗
Publisher: Taylor and Francis Ltd.
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology | 212 / 328 | 35th | Q3 |
| Genetics | 250 / 357 | 30th | Q3 |
| Molecular Medicine | 138 / 179 | 23rd | Q4 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2000–present, best quartile Q3, CiteScore 3.
Pharmacogenomics is Q3 in Pharmacology (rank 212 of 328), Q3 in Genetics (rank 250 of 357) and Q4 in Molecular Medicine (rank 138 of 179), by CiteScore 2025.
Pharmacogenomics is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 3, which places it in quartile Q3 at the 35th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.410, quartile Q3, with an H-index of 106.
Pharmacogenomics is published by Taylor and Francis Ltd. Its print ISSN is 1462-2416 and its online ISSN is 1744-8042.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Pharmacogenomics has an h-index of 113 and a 2-year mean of 1.99 citations per paper (OpenAlex). Its Scopus CiteScore is 3, quartile Q3. On 2-year citations it ranks #172 of 319 Scopus journals in Pharmacology.
Pharmacogenomics published 72 papers in 2025; its busiest recent year was 2017 with 162. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 99 research articles (2025–2026), authors are most often from United States (27.1%), Canada (9%) and China (6.3%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.